Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-118. (Canceled)

119. (Currently Amended) A composition comprising an Aβ peptide linked~~peptide linked~~ to a carrier which is a toxoid from a pathogenic bacterium to form a conjugate, wherein the Aβ peptide is Aβ1-7.

120. (Previously Presented) The composition of claim 119, wherein the conjugate comprises a plurality of additional copies of Aβ1-7.

121. (Previously Presented) The composition of claim 119, which comprises at least 10 μg of Aβ1-7.

122. (Previously Presented) The composition of claim 119, which comprises at least 20 μg of Aβ1-7.

123. (Previously Presented) The composition of claim 119, which comprises at least 50 μg of Aβ1-7.

124. (Previously Presented) The composition of claim 119, which comprises at least 100 μg of Aβ1-7.

125. (Previously Presented) The composition of claim 119, wherein the carrier is a diphtheria toxoid and Aβ1-7 is linked to the diphtheria toxoid by chemical crosslinking.

126. (Previously Presented) The composition of claim 125, wherein the amino terminus of Aβ1-7 is linked to the diphtheria toxoid.

127. (Previously Presented) The composition of claim 125, wherein the carboxyl terminus of Aβ1-7 is linked to the diphtheria toxoid.

128. (Previously Presented) The composition of claim 119, wherein the conjugate is expressed as a fusion protein.

129. (Previously Presented) The composition of claim 128, wherein the toxoid is a diphtheria toxoid and the amino terminus of Aβ1-7 is linked to the diphtheria toxoid.

130. (Previously Presented) The composition of claim 128, wherein the toxoid is a diphtheria toxoid and the carboxyl terminus of Aβ1-7 is linked to the diphtheria toxoid.

131. (Previously Presented) A composition comprising (a) an Aβ peptide linked to a carrier which is a toxoid from a pathogenic bacterium to form a conjugate, wherein the Aβ peptide is Aβ1-7 and (b) an adjuvant.

132. (Previously Presented) The composition of claim 131, wherein the conjugate comprises a plurality of additional copies of Aβ1-7.

133. (Previously Presented)The composition of claim 131, wherein the adjuvant comprises QS-21.

134. (Previously Presented) The composition of claim 133, which comprises at least 10 μg of Aβ1-7.

135. (Previously Presented) The composition of claim 133, which comprises at least 20 μg of Aβ1-7.

136. (Previously Presented) The composition of claim 133, which comprises at least 50 μg of Aβ1-7.

137. (Previously Presented) The composition of claim 133, which comprises at least 100 μg of Aβ1-7.

138. (Currently Amended) The composition of claim 133, wherein the toxoid is diphtheria toxoid [[7]] and Aβ1-7 is linked to the diphtheria toxoid by chemical crosslinking.

139. (Previously Presented) The composition of claim 138, wherein the amino terminus of Aβ1-7 is linked to the diphtheria toxoid.

140. (Previously Presented) The composition of claim 138, wherein the carboxyl terminus of Aβ1-7 is linked to the diphtheria toxoid.

141. (Previously Presented) The composition of claim 133, wherein the conjugate is expressed as a fusion protein.

142. (Currently Amended) The composition of claim 141, wherein the toxoid is diphtheria toxoid and the amino terminus of Aβ1-7 is linked to the diphtheria toxoid.

143. (Previously Presented) The composition of claim 141, wherein the toxoid is diphtheria toxoid and the carboxyl terminus of Aβ1-7 is linked to diphtheria toxoid.